These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 17205486)

  • 1. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy.
    Hope WW; Kruhlak MJ; Lyman CA; Petraitiene R; Petraitis V; Francesconi A; Kasai M; Mickiene D; Sein T; Peter J; Kelaher AM; Hughes JE; Cotton MP; Cotten CJ; Bacher J; Tripathi S; Bermudez L; Maugel TK; Zerfas PM; Wingard JR; Drusano GL; Walsh TJ
    J Infect Dis; 2007 Feb; 195(3):455-66. PubMed ID: 17205486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.
    van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA
    J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.
    Hope WW; Petraitis V; Petraitiene R; Aghamolla T; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4879-86. PubMed ID: 20713673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.
    Al-Nakeeb Z; Petraitis V; Goodwin J; Petraitiene R; Walsh TJ; Hope WW
    Antimicrob Agents Chemother; 2015 May; 59(5):2735-45. PubMed ID: 25712363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
    Manavathu EK; Cutright JL; Chandrasekar PH
    Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
    Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
    J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis.
    McCulloch E; Ramage G; Rajendran R; Lappin DF; Jones B; Warn P; Shrief R; Kirkpatrick WR; Patterson TF; Williams C
    J Clin Pathol; 2012 Jan; 65(1):83-6. PubMed ID: 22049217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
    Warn PA; Morrissey G; Morrissey J; Denning DW
    J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
    Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF.
    Sionov E; Mendlovic S; Segal E
    J Antimicrob Chemother; 2005 Sep; 56(3):594-7. PubMed ID: 16006446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis.
    Moosa MY; Alangaden GJ; Manavathu E; Chandrasekar PH
    J Antimicrob Chemother; 2002 Jan; 49(1):209-13. PubMed ID: 11751792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304.
    Defaveri J; Salazar MH; Rinaldi MG; Graybill JR
    Am Rev Respir Dis; 1990 Sep; 142(3):512-5. PubMed ID: 2202244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Prince RA; Chi J; Kontoyiannis DP
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3208-14. PubMed ID: 12234846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis.
    Ben-Ami R; Albert ND; Lewis RE; Kontoyiannis DP
    J Infect Dis; 2013 Apr; 207(7):1066-74. PubMed ID: 23303813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of antifungal agents and human monocytes on in vitro galactomannan release by Aspergillus spp. in liquid culture medium.
    Winn RM; Warris A; Gaustad P; Abrahamsen TG
    APMIS; 2007 Dec; 115(12):1364-9. PubMed ID: 18184406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model.
    Nagasaki Y; Eriguchi Y; Uchida Y; Miyake N; Maehara Y; Kadowaki M; Harada M; Akashi K; Shimono N
    J Antimicrob Chemother; 2009 Aug; 64(2):379-82. PubMed ID: 19465436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standardization of an experimental murine model of invasive pulmonary aspergillosis.
    Sheppard DC; Graybill JR; Najvar LK; Chiang LY; Doedt T; Kirkpatrick WR; Bocanegra R; Vallor AC; Patterson TF; Filler SG
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3501-3. PubMed ID: 17005844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis.
    Chandrasekar PH; Cutright JL; Manavathu EK
    Clin Microbiol Infect; 2004 Oct; 10(10):925-8. PubMed ID: 15373889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.
    Lestner JM; Howard SJ; Goodwin J; Gregson L; Majithiya J; Walsh TJ; Jensen GM; Hope WW
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3432-41. PubMed ID: 20439615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.